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H
eart disease is one of the leading
causes of death in the United States,
accounting for more than 600 000
deaths per year, with the majority of fatal-
ities due to coronary artery disease and
correlating heart failure.1 Due to limited
therapeutic options for severe MI and ad-
vanced heart failure, cell-based therapy
has emerged as a promising therapeutic
option.2 Particularly, cardiomyocytes (CMs)
derived from pluripotent stem cells (PSCs)
including both embryonic stem cells (ESCs)
and the recently identiﬁed induced pluripo-
tent stem cells (iPSCs)3,4 are regarded as one
of the most promising sources for cardiac
repair.5 CMs diﬀerentiated from PSCs have
unquestioned cardiomyogenic potential,6
in contrast to various adult stem cells, of
which the capacity to diﬀerentiate into
signiﬁcant numbers of deﬁnitive CMs is
controversial.7 PSC-derived CMs have a
clear cardiac phenotype, cardiac-type
electrophysiologic characteristics, and ex-
pression of expected genes and proteins.8
Several recent studies have shown that
transplantation of PSC-derived CMs into
rodent infarct models helped preserve car-
diac function.9
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ABSTRACT A signiﬁcant barrier to the therapeutic use of stem cells is poor cell
retention in vivo. Here, we evaluate the therapeutic potential and long-term
engraftment of cardiomyocytes (CMs) derived from mouse embryonic stem cells
(mESCs) encapsulated in an injectable nanomatrix gel consisting of peptide
amphiphiles incorporating cell adhesive ligand Arg-Gly-Asp-Ser (PA-RGDS) in
experimental myocardial infarction (MI). We cultured rat neonatal CMs in
PA-RGDS for 7 days and found that more than 90% of the CMs survived. Next,
we intramyocardially injected mouse CM cell line HL-1 CMs with or without
PA-RGDS into uninjured hearts. Histologic examination and ﬂow cytometry
analysis of digested heart tissues showed approximately 3-fold higher engraftment in the mice that received CMs with PA-RGDS compared to those
without PA-RGDS. We further investigated the therapeutic eﬀects and long-term engraftment of mESC-CMs with PA-RGDS on MI in comparison with PBS
control, CM-only, and PA-RGDS only. Echocardiography demonstrated that the CM-only and CMþPA-RGDS groups showed higher cardiac function at week 2
compared to other groups. However, from 3 weeks, higher cardiac function was maintained only in the CMþPA-RGDS group; this was sustained for
12 weeks. Confocal microscopic examination of the cardiac tissues harvested at 14 weeks demonstrated sustained engraftment and integration of mESC-CMs
into host myocardium in the CMþPA-RGDS group only. This study for the ﬁrst time demonstrated that PA-RGDS encapsulation can enhance survival of
mESC-derived CMs and improve cardiac function post-MI. This nanomatrix gel-mediated stem cell therapy can be a promising option for treating MI.
KEYWORDS: PA-RGDS . myocardial infarction . pluripotent stem cell . cardiomyocyte . cardiac regeneration
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However, it is now widely recognized that retention
of CMs delivered into heart is surprisingly low. The
survival rate is only 50% immediately after injection
and drops to 10% in as little as 1 week.10 The longest
reported survival of human PSC-derived CMs after
direct injection into murine myocardium did not ex-
ceed 12 weeks.11 These issues have necessitated the
development of biomaterial-based strategies in which
extracellular matrix (ECM)-mimicking biomaterials can
promote cell survival, maturation, and integration with
the host myocardium by providing a nurturing envi-
ronment with the necessary factors, frequently lacking
in the infarcted heart.12 Recent developments in nano-
scale design allow us to tailor biomaterials to very
closely mimic the ECM, which can provide the cells
with a protective microenvironment while simulta-
neously promoting localized ECM formation and inter-
cellular connections.
Accordingly, we aimed to develop a novel strategy
to enhance the therapeutic eﬀects of PSC-derived
CMs by using self-assembled biodegradable peptide
amphiphile (PA) nanomatrices. PAs are a class of self-
assembling peptides that combine a short hydro-
phobic sequence with a hydrophilic, bioactive peptide
sequence, presenting a promising approach to achieve
this goal (Figure 1).13 For this study, we generated
PA-RGDS, an ECM-mimicking injectable nanomatrix, by
incorporating cell adhesive ligand Arg-Gly-Asp-Ser (RGDS)
and matrix metalloprotease-2 (MMP-2) degradable
sequence Gly-Thr-Ala-Gly-Leu-Ile-Gly-Gln (GTAGLIGQ)
into the PA.14 The amphiphilicity of this PA allows
self-assembly into three-dimensional (3D) networks of
high aspect ratio nanoﬁbers similar to ECM protein
nanoﬁbers under physiological conditions. In addition,
RGDS, a ﬁbronectin-derived cell adhesive ligand, is
incorporated into PA to promote cell adhesion and
survival, and its favorable eﬀect has been extensively
conﬁrmed by a variety of cell types such as human
mesenchymal stem cells, human umbilical vein en-
dothelial cells, aortic smoothmuscle cells, and pancrea-
tic beta cells.1528 Lastly, incorporation of MMP-2
degradable sequences into PAs is expected to allow
progressive degradation of the scaﬀold and re-
placement by natural ECM produced by the cells, as
the heart tissue displays increased MMP production
under ischemic conditions.2931 It also enhances the
migration of encapsulated CMs into the host myocar-
dium. These PA-RGDS closelymimic the physical as well
as the biochemical complexity of the native ECM.
Hence, we hypothesized that encapsulation of
mESC-derived CMs with injectable PA-RGDS nano-
matrix gel would improve cardiac function post-MI
through increased cell survival and retention within
the host myocardium. Subsequently, we found that
this PA-RGDS nanomatrix enabled long-term survival
of mESC-CMs in ischemic hearts and their integration
into host myocardium and promoted cardiac repair
following experimental MI.
RESULTS
PA-RGDS Is Not Cytotoxic to Cardiomyocytes. To examine
the cytotoxicity of PA-RGDS to CMs, neonatal rat
cardiomyocytes (NRCMs) were embedded within PA-
RGDS nanomatrix gel and cultured for 7 days under
normal CM culture conditions, and Live/Dead staining
was performed. As shown in Figure 2, the majority of
NRCMs encapsulated with PA-RGDS were alive (green)
after 7 days of culture, and less than one-tenth of cells
Figure 1. Structure of PA-RGDS.
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were dead (red). These data indicate that PA-RGDS
gel supports the viability of CMs over a 7-day culture
period (live vs dead: 90.7 ( 6.2% vs 9.3 ( 0.8%, p <
0.001) (Figure 2).
Cytoprotective Effects of PA-RGDS Encapsulation against
Oxidative Stress. Since a main cause of poor survival of
transplanted cells in the ischemic heart is oxidative
stress,12 we investigated whether encapsulation of the
CMs with PA-RGDS could increase their survival when
exposed to H2O2, which simulates ischemic condi-
tions in vitro. As shown in Figure 3A, the results from
live/dead staining demonstrated that encapsulation of
NRCMs with PA-RGDS significantly improved viability
compared to NRCMs without encapsulation (p < 0.001)
(Figure 3A). Concordantly, CM/PA-RGDS constructs
exposed to H2O2 released significantly less LDH com-
pared to bare NRCMs (p < 0.001) (Figure 3B). These
results indicate that encapsulating the CMs with PA-
RGDS can promote CM survival under conditions of
oxidative stress.
In Vivo Degradation Kinetics of PA-RGDS. To examine the
in vivo degradation behavior of the PA-RGDS, PA-RGDS
that was prelabeled with CM-DiI, a red fluorescent
dye (Supplementary Figure 1A), was allowed to self-
assemble into a three-dimensional gel. The gels were
then intramyocardially injected into the hearts of C57B6
mice, after myocardial infarction (MI) was induced
by ligation of the left anterior descending coronary
artery.32,33 Themicewere then euthanized at 1, 2, 4, and
6 weeks after injections (N = 3 per time point), and the
hearts were harvested. Through histological evaluation
under confocal microscopy, we found that the amount
of red fluorescent PA-RGDS was gradually reduced in
heart sections over time andwas almost degraded in all
three hearts by 6 weeks (Supplementary Figure 1B).
PA-RGDS Increased Retention of Transplanted Cardiomyocytes
in Intact Heart. To investigate the effects of PA-RGDS
on CM engraftment and survival in vivo, we prelabeled
cultured HL-1 CMs,34 an immortalized mouse CM cell
line, with CM-DiI and injected them into the intact
hearts of athymic nude mice (2  105 cells per mouse)
in the absence or presence of PA-RGDS. After sacrificing
mice at 1 week, we performed immunostaining and
flow cytometry. Confocal microscopic examination de-
monstrated that the number of engrafted CMs was
substantially higher in the PA-RGDS-encapsulated HL-1
CM group than in the bare HL-1 CM group (Figure 4A).
For more accurate quantification of these engrafted/
surviving cells, weperformed flow cytometry analysis of
enzymatically digested heart tissues (Figure 4B).35 We
found that the retention rate of HL-1 CMs was approxi-
mately 3-fold higher when encapsulated with PA-RGDS
than without encapsulation. Immunohistochemistry
further showed that the injected CMs in PA-RGDS
integrated well within host myocardium and main-
tained expression of cardiac-specific protein ACTN2
(or R-sarcomeric actinin). These results suggest that
encapsulationwith PA-RGDS significantly increased the
retention and integration of the injected CMs into the
heart in vivo (Figure 4C).
Generation and Purification of Cardiomyocytes from Mouse
Embryonic Stem Cells. To generate CMs, undifferentiated
mouse ESCs (J1) were induced to form EBs. Day-4 EBs
were replated as monolayers in the presence of ascor-
bic acid (Supplementary Figure 2A).32 Spontaneously
beating clumps began to appear 34 days later
Figure 2. Evaluation of cellular behaviors of cardiomyocytes encapsulated in PA-RGDS. Representative Live/Dead assay
images of NRCMs after 7 days of culture in normoxic conditions. Bar graph summarizes the results of the Live/Dead assay.
*p < 0.0001; N = 3. Scale bars, 20 μm.
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(Supplementary Movie 1). A prior study demonstrated
that CMs can be purified from differentiating PSCs by
the addition of lactate to glucose-depleted medium,
due to the metabolic differences between CMs and
non-CMs.36 Therefore, at 7 days,we replaced the culture
medium with glucose-depleted medium supplemen-
ted with 1 mM lactate, and the cells were cultured
for another 7 days. Flow cytometry analysis showed
that the percentage of cardiac troponin T (TNNT2)-
positive cells was increased from 48.5 ( 5.1% at day
11 (before lactate treatment) to 77.2 ( 6.8% at day 18
(Supplementary Figure 2B). Immunocytochemistry
further demonstrated that a majority of differentiated
mESCs expressed CM-specific proteins ACTN2, TNNT2,
and MYH6/7 (or R/β MHC), confirming their CM nature
(Supplementary Figure 2CE). Collectively, these re-
sults indicate that our new differentiation system can
successfully generate enriched CMs from mESCs.
CM/PA-RGDS Improved Cardiac Function and Reduced Scar
Formation after MI. Next, we investigated the therapeu-
tic effects of these enriched mESC-CMs encapsulated
with PA-RGDS on MI. After the mice were randomized
to four groups, each group received the following
materials directly into the periinfarct region immedi-
ately after MI: mESC-CMs encapsulated with PA-RGDS,
mESC-CMs only, PA-RGDS only, and phosphate-
buffered saline (PBS) control. Cells were prelabeled
with CM-DiI before cell injection for tracking in histo-
logical sections. Echocardiography was performed
weekly for 4 weeks (Figure 5A). One week post-MI,
fractional shortening (FS) and ejection fraction (EF) did
not differ significantly among the groups. At week 2, EF
and FS were higher in the mESC-CM only and mESC-
CMþPA-RGDS groups compared to the PA-RGDS only
and PBS groups, although the differences did not reach
statistical significance. From 3 weeks, the EF and FS
were continuously increased in the mESC-CMþ
PA-RGDS group, while reduced in the mESC-CM only
group and showed a significant difference between
the mESC-CMþPA-RGDS group compared to the
other three groups at 4 weeks (Figure 5A). Masson's
trichrome staining of the cardiac tissue harvested at
4 weeks demonstrated that the mESC-CMþPA-RGDS
group showed significantly reduced fibrosis compared
to the other three groups (p < 0.05) (Figure 5B).
Fluorescent microscopic examination of the heart
sections harvested at 4weeks showed that the number
of engrafted DiI-positive mESC-CMs was signiﬁcantly
higher in the mice receiving CMs encapsulated with
PA-RGDS compared to those receiving only mESC-
CMs (Figure 5C). Immunohistochemistry with MHC6/7
antibody further demonstrated that the injected CMs
encapsulated with PA-RGDS were robustly engrafted
and integrated into the host myocardium, forming
clusters, and expressed representative CM proteins
(Figure 5D).
Sustained Therapeutic Effects of mESC-CMs with PA-RGDS.
Prior studies reported that the beneficial effects of
ESCs were substantially diminished by 34 weeks,
mostly due to massive cell death or ejection from the
myocardium.11 Hence, we monitored the long-term
therapeutic effects of the mESC-CMþPA-RGDS-treated
group in comparison to the CM-only injected group
over 12 weeks (Figure 6A). Echocardiography showed
that both EF and FS were slightly decreased until
8 weeks but were maintained during the rest of the
follow-up in the mESC-CMþPA-RGDS group, while the
indices were progressively decreased in the mESC-CM-
only group (Figure 6A). We further examined the
characteristics of engrafted mESC-CMs in histologic
sections of the harvested hearts at 14 weeks. Micro-
scopic examination after DAPI counterstaining showed
that a substantial number of DiI-labeled CMs were still
visible in the heart tissues that received mESC-CMs
with PA-RGDS, while DiI-labeled CMs were hardly seen
in the mESC-CM-only group (Figure 6B). Immunostain-
ing for MYH6/7 demonstrated that these engrafted
CMs were well integrated into the host myocardium,
and concomitant staining with Gja1 further showed
Figure 3. Cytoprotective eﬀects of PA-RGDS encapsulation
against H2O2. (A) Encapsulation of NRCMs with PA-RGDS
increased cell survival after H2O2 (200 μM) treatment as
determined by the Live/Dead assay. *p < 0.001 compared
with CMonlygroup;N=3. Scale bars, 20μm. (B) Cell viability
was also measured by extracellular release of LDH.
*p < 0.001 compared with H2O2-untreated controls.
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formation of gap junctions between the engrafted CMs
and host CMs (Figure 6D). Together, these data suggest
that myocardial injection of mESC-CMs encapsulated
with PA-RGDSmarkedly enhanced cell retentionwithin
the injuredmyocardium, induced integration of mESC-
CMs with host myocardium, and sustained therapeutic
effects over several months.
DISCUSSION
The potential success of stem cell-based therapy for
cardiac regeneration has been consistently hindered
by a critical inability to retain implanted cells in heart.37
In most stem cell studies, myocardially injected cells
have a very low survival rate.38 Thus, various natural and
artiﬁcial biomaterials have been assessed for cardiac
repair with adult or pluripotent stem cells.12,3840
Among them, PA-based materials have emerged as a
promising option due to rapid gel-like 3D network
formation, ECM-like nanostructures, modular designs,
and biodegradability. Although PA-based biomaterials
were used for cell delivery of bone marrow-derived
cells, there have not been any studies that explored
their eﬀects on pluripotent stem cell-derived CMs and
their long-term fate.41
The present study shows that PA-RGDS is able to
enhance cell retention and improves cardiac function.
While the cardiac function of the mESC-CM-only in-
jected group was improved to a similar extent to
the mESC-CMs encapsulated with PA-RGDS group by
2 weeks after treatment, suggesting regenerative ef-
fects of bare mESC-CMs at an early phase, such eﬀects
disappeared after 3 weeks. Histologic examination
clearly demonstrated that the mESC-CM-only injected
group showed virtually complete disappearance of the
injected cells over 14 weeks. However, the PA-RGDS-
encapsulated mESC-CM group showed long-term cel-
lular engraftment and integration into host myocar-
dium, expressed mature and structural CM proteins
such as cTNT and MHC6/7, formed gap junctions with
host CMs, and maintained improved cardiac function,
indicating the eﬀectiveness of PA-RGDS on the func-
tion of injected mESC-CMs. These results indicate that
Figure 4. Survival and engraftment of HL-1 CMs after injection into uninjured mouse hearts. Seven days after injection of
dilabeled (red) HL-1 CMs encapsulated with or without PA-RGDS into intact mouse hearts, mice were sacriﬁced and hearts
were collected. (A) Confocalmicroscopic images of sectioned heart tissue after DAPI staining. DiI: redﬂuorescence. DAPI: blue
ﬂuorescence. Scale bars, 200 μm. (B) Quantiﬁcation of engrafted HL-1 CMs by ﬂow cytometry following cardiac tissue
digestion into cell suspension; N = 3. (C) Confocal microscopic images of sectioned heart tissues after staining with ACTN2 in
the mice receiving HL-1 CMs encapsulated with PA-RGDS. Green: ACTN2 staining. Scale bars, 20 μm.
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even though the gels may degrade by week 6, the cells
delivered by the gels show signiﬁcant long-term favor-
able outcomes. From this, we may infer that PA-RGDS
indeed provides the cells with a protective environ-
ment during the early stage of implantation, which is
critical for cell engraftment and survival, leading to
improved retention and eventual interactions with
host tissue.
This study is the ﬁrst to investigate the therapeutic
eﬀects of CMs derived from PSCs in combination with
Figure 5. Favorable eﬀects of mESC-CMs with PA-RGDS on mouse experimental MI. (A) Improvement of cardiac function in
mice receiving mESC-derived CMs with PA-RGDS. Fractional shortening (FS: left) and ejection fraction (EF: right) were
signiﬁcantly higher in the mESC-CMþPA-RGDS group compared to the three other groups measured by echocardiography.
Repeated-measures ANOVA was used for statistical analyses. *p < 0.05; N = 610 per group. (B) Representative images from
the four treated groups showing cardiac ﬁbrosis after staining with Masson's trichrome in the hearts harvested 4 weeks after
MI and their quantiﬁcation results. *p < 0.05; N = 6. (C) Confocal microscopic images of heart sections collected 4 weeks after
MI and cell injection showed that the engraftment of DiI-labeled mESC-CMs was substantially higher when cells were
encapsulated. *p < 0.05; N = 3. (D) The Dil-mESC-CMs (red ﬂuorescence) expressed MYH6/7 (green) and were well integrated
into host myocardium. Scale bars, 20 μm.
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injectable PA-RGDS nanomatrix gel. While there have
been numerous studies examining the eﬀects of bio-
material-mediated cell therapy for cardiac regenera-
tion, most studies employed adult stem cells such as
mesenchymal stem cells and endothelial progenitor
cells. However, the trans-diﬀerentiation potential of
those cells into CMs is limited and their underlying
mechanism is paracrine or humoral eﬀects on surviving
myocardium.42 Ideally, it would be better to generate
new myocardial tissues in hearts by providing new
CMs. Here, our strategy was to meet this end by
combining PSC-derived CMs, which have the clearest
Figure 6. Sustained therapeutic eﬀects of mESC-CMs with PA-RGDS on a mouse model of MI. (A) EF and FS measured by
echocardiography were signiﬁcantly greater in the mESC-CMþPA-RGDS group compared to the mESC-CM-only injected
group. Repeated-measures ANOVA was used for statistical analyses. *p < 0.05. N = 6 per group. (B) Representative confocal
microscopic images showing engraftment of DiI-labeledmESC-CMs in hearts harvested at 14weeks compared to the CM-only
injected group and the CMs with PA-RGDS group and their quantiﬁcation (lower panel) *p < 0.05. N = 5. (C, D) Confocal
microscopic images show integrationof implantedmESC-CMs (DiI, redﬂuorescence) into ischemicmyocardium, as evidenced
by expression of Myh6/7 (C, green), Actn2 (D, green), and Gja1 (D, white). Hearts harvested from the mESC-CMþPA-RGDS
group at 14 weeks. Scale bars, 20 μm.
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potential for generating new CMs in injured hearts,2
with PA-RGDS, which has the potential to address low
cell survival.
The PA-RGDS used in this study was designed to
provide a protective microenvironment for CMs in vivo
by incorporating PAs with RGDS cell adhesive ligands,
MMP-2 degradation sites, and self-assembly into three-
dimensional nanoﬁber networks. The rapid polymeri-
zation kinetics of the PA-RGDS allows eﬀective entrap-
ment of mESC-derived CMs at the site of delivery,
resulting in improved cell retention. The incorporation
of RGDS cell adhesive ligand promotes the adhesion
and retention of CMs inside the nanomatrix gel,
especially since PSC-derived CMs have poor adhesion
capacities. MMP-2 degradable sites play an important
role in the slow integration of implanted CMs with host
myocardium through their controlled degradation
of the nanomatrix gel, as evidenced by the results of
the degradation study. In addition, the 3D nanoﬁber
network structure allows the transfer of nutrients and
growth factors by diﬀusion, thereby promoting cell
viability. Another important aspect of the PA-RGDS
is the physical properties of the gels, which can be
tuned to provide mechanical strength.43 It has been
previously assessed that the mechanical properties
of PA-RGDS self-assembled under similar conditions
determined by the storage modulus (G0) have been
observed to be around 100 Pa,43 which puts them in
the category of moderately stiﬀ hydrogels with higher
potential for cell encapsulation and delivery for soft
tissue engineering applications such as cardiovascular
tissues.43 PA-RGDS nanomatrix gels were also observed
to be structurally stable with well-deﬁned cylindrical
shape and increased durability for handling and trans-
port. This is particularly important for early cell survival,
as cardiac tissue scaﬀolds require enough mechanical
strength to resist the cardiac cycle, but enough ﬂex-
ibility to allow the contractile function of implanted
CMs. While the exact required mechanical stiﬀness to
match native heart tissue remains unknown due to the
vast changes in heart stiﬀness during diseased stages,
the mechanical strength of PA-RGDS can be tuned for
the application as previously reported.43 Alongwith the
biochemical cues provided by RGDS and the MMP-2
degradable sequences, this property may be important
for initial retention and survival of implanted CMs.
CONCLUSION
This study demonstrates that PA-RGDS gel has the
capacity to augment survival and integration of PSC-
derived CMs, which leads to generation of new CMs
over a fewmonths and improves cardiac function. As it
is biocompatible and already approved by FDA for
clinical use, this injectable PA-RGDS-mediated pluripo-
tent stem cell therapy can develop into a novel therapy
for repairing injured hearts.
METHODS
Peptide Amphiphile Synthesis. Two peptide amphiphiles,
C16-GTAGLIGQRGDS (PA-RGDS) and C16-GTAGLIGQS (PA-S),
were synthesized via Fmoc-chemistry using an Aapptech Apex
396 peptide synthesizer as previously described.23,27,28,4345
The peptides were then alkylated at the N-termini via two 12 h
reactions with palmitic acid and a mixture of o-benzotriazole-
N,N,N0 ,N0-tetramethyluronium hexafluorophosphate and diiso-
propylethylamine dissolved in dimethylformamide. This was
succeeded by cleavage from the resin and deprotection for
3 h, using a 40:1:1:1 cocktail of trifluoroacetic acid (TFA),
deionized water, triisopropylsilane, and anisole. The collected
samples were subjected to rotary evaporation to remove excess
TFA, precipitated in ether, and lyophilized. Matrix-assisted laser
desorption ionization time-of-flight (MALDI-TOF) mass spectro-
metry was utilized to confirm successful synthesis of PAs.
Self-Assembly of Peptide Amphiphile Gels. Stock solutions of
PA-RGDS and PA-S [2% (weight/volume)] were individually pre-
pared, and their respective pH was adjusted to 7 using sodium
hydroxide (NaOH). The two PAs were then mixed in 1:1 molar
ratio, and self-assembly into three-dimensional hydrogels was
induced by combining 50 μL of PA solution with a mixture
containing 15 μL of 0.1 M CaCl2 and 25 μL of cell suspension.
The molar ratio of PA and Ca2þ was held constant at 2.27,43
Isolation and Culture of Rat Neonatal Ventricular Cardiomyocytes. To
isolate neonatal rat ventricular cardiomyocytes (NRCMs), the
heart tissues from 3- to 5-day-old neonatal rats were carefully
dissected and digested for 12 h with 50 U/mL collagenase
type II (Worthington Biochemicals) in calcium- and bicarbonate-
free Hanks' buffer with HEPES at room temperature, followed by
overnight digestion with 0.5 mg/mL of trypsin (Invitrogen) at
4 C. The number of noncardiac cells such as fibroblasts and
endothelial cells wasminimized by differential plating. A total of
2  106 isolated NRCMs were plated in a 100 mm dish and
cultured at 37 C in growthmedia containingDulbecco'smodified
Eagle's medium/Ham's F-12 [1:1 (v/v); Invitrogen] supplemented
with 10% fetal bovine serum (FBS) and 100 units/mL penicillin/
streptomycin (Invitrogen). Following 24h of culture, themedium
was replaced by serum-free medium supplemented with
1% insulin-transferrin-selenium (ITS) in DMEM/F12 [1:1 (v/v)]
for 24 h.46
Cultivation of HL-1 Cardiomyocytes. HL-1 CMs, a cell line derived
fromadultmouse atria,were received fromDr.WilliamClaycomb
(Louisiana State University, LA, USA) and cultivated as described
in the literature.34 The HL-1 CMs were plated in a dish coated
with 12.5 μg/mL fibronectin (Sigma) and 0.02% gelatin (Sigma)
andmaintained in complete Claycombmedium (Sigma) supple-
mented with 10 μM norepinephrine (Sigma), 0.3 mM L-ascorbic
acid (Sigma), 4 mM L-glutamine (Gibco), and 10% FBS (Sigma) in
a 5% CO2 atmosphere at 37 C.
Evaluation of Cytotoxicity of PA-RGDS. In order to examine if PA-
RGDS is cytotoxic to CMs, we performed Live/Dead staining
(Invitrogen) for CMs cultured in PA-RGD gel. A total of 5  105
freshly isolated and cultured NRCMs contained in 50 μL of
advanced DMEM media with 3% FBS were mixed with 50 μL of
the PA-RGDS solution followed by the addition of 14 μL of CaCl2
(0.1 M) solution to initiate gel polymerization. Subsequently, the
CM/PA-RGDS constructs were cultured in CM culture medium
containing advanced DMEM/F12 supplemented with 3% FBS
and ITS for 7 days and harvested for Live/Dead staining. To show
the live cell distribution, confocal images (z-stacks) were cap-
tured at either the center or the edge of CM/PA-RGDS constructs
using a Zeiss LSM 510 Meta confocal laser scanning microscope
and LSM 510 Image software (CLSM, Carl Zeiss). Quantification
of live or dead cells was performed using ImageJ software.
Evaluation of in Vivo Biodegradation of PA-RGDS. To explore the
nature of degradation of the PA-RGDS hydrogel in vivo, we
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labeled PA-RGDSwith CM-DiI, a red fluorescent dye, for tracking
gels and intramyocardially injected it into the hearts of C57B6
micewheremyocardial infarctionwas induced by ligation of the
left anterior descending coronary artery. The mice were then
euthanized 1, 2, 4, or 6 weeks after injections for histological
evaluation (N = 3 per time point).
Assessment of Cytoprotective Effects of PA-RGDS on CMs against Oxidative
Stress. To investigate whether encapsulation of CMs with PA-
RGDS could provide cytoprotective effects against oxidative
stress, we generated CM/PA-RGDS constructs by the method
described above and cultured them in CM culture medium
containing hydrogen peroxide (H2O2) (200 μM), simulating con-
ditions of myocardial ischemia in vitro. Following 2 h exposure to
hydrogen peroxide, CM/PA-RGDS constructs were harvested for
Live/Dead staining. Culturemediumwas removed and subjected
to lactase dehydrogenase (LDH) assay (LDH cytotoxicity assay kit,
Sigma).46 Briefly, 50 μL of culture medium was collected from
cultured CM/PA-RGDS constructs (in triplicate) and transferred
into a 96-well plate. After adding an equivalent volume of LDH
reagent into each well, the absorbance was measured using a
spectrophotometer at a wavelength of 492 nm with a reference
wavelength of 620 nm. For more accurate measurements, the
absorbance of the no-cell controls was subtracted from the
readings of CM samples.
Flow Cytometry Analyses of Cell Retention in the Hearts after Tissue
Digestion. To investigate the effects of PA-RGDS on cell engraft-
ment and cell survival in vivo, cultured HL-1 CMswith or without
PA-RGDS gel encapsulation were prelabeled with CM-DiI, a red
fluorescent dye, and intramyocardially injected into the hearts
of uninjured athymic nudemice (5 105 cells permouse) through
30G needles at two sites of myocardium (N = 3 per group). After
7 days, the hearts were harvested for further analyses. For
quantification of surviving HL-1 CMs, we performed flow cytome-
try analysis after tissue digestion. The cell-injected areas in each
heart were removed, minced, and digested with collagenase type
II (50 U/mL; Worthington Biochemicals) at 37 C for 6090 min.
Single-cell suspensions were prepared by filtering through a
50 μm strainer. Cells were then analyzed by a C6 flow cytometer
(BD Biosciences), and flow cytometric data were analyzed with
FlowJo software (Treestar).35
Immunocytochemistry and Immunohistochemistry. Cells or frozen
heart sections prepared with OCT compound (Tissue-TeK 4583,
Sakura Finetek Inc.) were fixed with 4% paraformaldehyde
for 10 min at room temperature, washed twice with PBS, and
permeabilized with 0.1 or 0.5% Triton X-100 in PBS for 10 min or
1 h. Samples were then blocked with 1% BSA in PBS for 60 min
at room temperature and incubated with either anti-ACTN2
(Sigma; 1:100), or mouse anti-TNNT2 (NeoMarkers; 1:100), or
mouse anti-MYH6/7 (Abcam; 1:100), or Gja1 (Sigma; 1:100) at
4 C overnight. The samples were again washed three times
with PBS containing 1%Tween 20 and then incubatedwith anti-
mouse IgGAlexa Fluor 594 (Invitrogen; 1:1000) or antimouse
IgGAlexa Fluor 488 (Invotrogen; 1:1000) in PBS for 60 min
at room temperature. DAPI was used for nuclear staining. The
samples were visualized under a fluorescent microscope (Nikon)
or a Zeiss LSM 510Meta confocal laser scanningmicroscope and
analyzed by LSM 510 Image software (CLSM, Carl Zeiss).
Mouse ESC Culture and Differentiation. mESCs (J1) were cultured
in high-glucose Dulbecco's modified Eagle medium (DMEM)
supplemented with 10% FBS (Atlanta Biologicals), 1% non-
essential amino acids solution, 1% L-glutamine, 0.1 mM β-
mercaptoethanol, 1% penicillin/streptomycin, and 2000 U/mL
mouse LIF (Millipore) on feeder layers of mitotically inactivated
STO cells, a mouse embryonic fibroblast line (ATCC). To differ-
entiate mESCs into cardiac lineage, an embryoid body (EB)
method was employed with some modifications.47 EBs were
formed by suspending the cells at 107 cells/mL in 10 mL of
differentiation media: alpha-modified Eagle medium (R-MEM;
Invitrogen) supplemented with 10% FBS, 1% nonessential
amino acids, 1% L-glutamine, 1% β-mercaptoethanol, L-ascorbic
acid (50 μg/mL; Sigma), and 1% penicillin/streptomycin. Differ-
entiation medium was changed every day. Four days after
the initiation of EB formation, floating EBs were collected
by centrifugation and transferred to fibronectin (Sigma)-
coated plates to be attached. Then these attached EBs on
fibronectin-coated plates were cultured in nonserum culture
medium: DMEM/F12 (Invitrogen) supplemented with L-ascorbic
acid (50 μg/mL) for further differentiation into CMs. Typically,
beating cells appeared on day 7.
Enrichment of mESC-Derived Cardiomyocytes Using Lactate. To en-
rich the CMs from mESC differentiation cultures, lactate-based
purification was applied.36 The cardiomyogenically differen-
tiated mESCs at day 11 were dissociated with trypsin (0.05%),
replated in fibronectin-coated dishes containing freshly pre-
pared glucose-free advanced DMEM (no glucose, no pyruvate;
Invitrogen) supplemented with 1 mM lactate, 0% FBS, 1% non-
essential amino acids, 1% L-glutamine, 1% β-mercaptoethanol,
and 1% penicillin/streptomycin, and continuously cultured for
7 days. Mediumwas changed every 2 days in order to eliminate
dead cells. After 7 days of culture in lactase-containing media,
the enriched mESC-derived CMs were dissociated with trypsin
(0.05%), transferred to fibronectin-coated dishes, and further
cultured with R-MEM supplemented with 3% FBS and ITS. To
quantify the CMs, flow cytometric analysis following cell per-
meabilization was performed using ACTN2 antibody (Sigma).32
Induction of Myocardial Infarction and Cardiomyocyte Transplantation.
All animal experiments were approved by the Emory University
Institutional Animal Care and Use Committee and were per-
formed in accordance with federal guidelines. Studies were
performed using male athymic nude mice (Foxn1nu) (Harlan,
USA). Myocardial infarction and cell implantation were per-
formed as described previously.48 MI was induced in mice by
ligation of the left anterior descending coronary artery, and
cells or other reagents were intramyocardially injected through
30 G needles at two different sites in the border zone of the
myocardium immediately after surgery. Mice were randomly
assigned into four treatment groups: (i) PBS as a control group,
(ii) 2  105 mESCs-derived CMs only, (iii) PA-RGDS only, or (iv)
2  105 mESCs-derived CMs encapsulated with PA-RGDS. Due
to the limiting factor of murine heart size and the requirement
to deliver a large quantity of cells, only one concentration ratio
of PA (2  105 mESCs-derived CMs32) to cells was used for the
studies. All CMs were obtained from the same differentiation
batch and prelabeled with CM-DiI (red fluorescence) before cell
injection for cell tracking in histology. The number of mice was
1012 per experimental group.
Echocardiography. Echocardiography was performed at week
1, 2, 4, 8, and 12 after surgery using a Vevo 770TM Imaging
System (VisualSonics, Inc.) as previously described.33 Ejection
fraction and fractional shortening were measured using two-
dimensional and M-mode images.
Masson's Trichrome Staining and Measurement of Fibrosis. To deter-
mine the circumferential fibrosis area, heart tissueswere harvested
4 weeks after MI induction and treatments and stained with
Masson's trichrome (Sigma-Aldrich) as previously described.49
Fibrosis and LV areas were measured, and average ratios
(fibrosis:LV areas) were calculated.
Statistical Analyses. All data were expressed as mean ( SEM.
Student's t test or ANOVA test was used for the statistical
analysis. Repeated-measures ANOVA was used for data shown
in Figure 6A. Values of p < 0.05 were considered to denote
statistical significance. All statistical analyses were conducted
using SPSS 20.0 (SPSS Inc.).
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